In adults with type 2 diabetes on antipsychotics, weight loss of at least 5% occurred in 61.29% with semaglutide plus metformin versus 38.7% with metformin alone.
In plain wordsIn adults with diabetes on antipsychotics, more people lost 5% or more of their weight with semaglutide plus metformin (61.29%) than with metformin alone (38.7%).
- Peptide
- Semaglutide
- Outcome
- IncreaseWeight loss of 5% or more from baseline
- Study
n = 62
- Comparator
- Metformin monotherapy
- Analysis
- Primary
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- Dose not stated
Measurements
- Responders with weight loss >=5%
- 61.29%
- semaglutide plus metformin
- Responders with weight loss >=5%
- 38.7%
- metformin alone
Source sentences
38.7% (12/31) of patients in the monotherapy group achieved the primary outcome of weight loss ≥ 5% from baseline vs. 61.29% (19/31) in the combination group (p = 0.04).
3 context sentences(design, population, supporting numbers)
The primary endpoint was defined as weight loss ≥ 5% from baseline.
This was a single-center, retrospective study evaluating patients ≥ 18 years of age receiving care at Michael E.
Subjects were identified by use of antipsychotic (quetiapine, risperidone, paliperidone, olanzapine, clozapine) with concomitant use of monotherapy or combination therapy.